3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
Cyclophosphamide
11
Cytarabine
8
Methotrexate
6
Etoposide
6
Dexamethasone
6
Vincristine
5
Radiotherapy
5
Doxorubicin
5
Daunorubicin
5
pegaspargase
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Mercaptopurine
4
Idarubicin
4
gamma-Globulins
3
fludarabine phosphate
3
Whole-Body Irradiation
3
Prednisone
3
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
3
Methylprednisolone
3
Gemtuzumab
3
Filgrastim
3
Clofarabine
3
Ciprofloxacin
3
Busulfan
3
etoposide phosphate
2
blinatumomab
2
Thioguanine
2
Melphalan
2
Karyotyping
2
Injections, Spinal
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Leukemia
×
Clavulanic Acid
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled